CF Terms | Claire's Place Foundation

CF Terms

- Absorption/Malabsorption
- Adverse Effect
- Aerosolized
- Airway Clearance Techniques or ACTs
- Airways
- Alveoli
- Aminoglycosides
- Anti-Inflammatory Agent
- Antibiotic
- Antibody
- Antimicrobial
- Approved Drug
- Assay
- Autosomal Recessive
- Bacteria
- Biofilm
- Biomarker
- Blind Trial
- Blood Pressure
- BMI – Body Mass Index
- Broad Spectrum Antibiotic
- Bronchiectasis
- Bronchoalveolar Lavage (BAL)
- Bronchoscopy
- Burkholderia Cepacia
- Carrier
- CC – Cubic Centimeter
- Cell
- Central Venous Catheter
- Cephalosporins
- CFRD – Cystic Fibrosis-Related Diabetes
- CFTR – Cystic Fibrosis Conductance Transmembrane Regulator
- Chromosome
- Chronic
- Cirrhosis
- Clinical
- Clinical Assessment
- Clinical Investigator
- Clinical Study
- Clinical Trial
- Compassionate Use
- Computed Tomography (CT)
- Condensate
- Confidentiality
- Contraindicated
- Contrast Enhanced Ultrasound
- Control Group
- CPT – Chest Percussion Therapy
- Cystic fibrosis
- Deficiency
- Deterioration
- Digestion
- Digestive Enzymes
- Double Blind Trial
- Drug-Drug Interaction
- E Coli – Escherichia coli
- EMLA – Eutectic Mixture of Local Anesthetics
- Endocrine
- Esophagus
- Exacerbation
- Exclusion/Inclusion Criteria
- Exhalation
- Exocrine Pancreatic Insufficiency (EPI)
- Expanded Access
- Experimental Drug
- Failure to Thrive
- FDA – Food and Drug Administration
- FEV1
- Fundoplication
- G-tube
- Gastroesophageal reflux disease (GERD)
- Gene
- GI or Gastroenterology
- Glucose
- Good Clinical Practice
- Gram-negative bacteria
- Gram-positive bacteria
- Hormone
- Hyperglycemia
- Hypoxemia
- Immunity
- In Vivo
- Infectious Disease
- Informed Consent
- Informed Consent Document
- Inhalation
- Insulin
- Intestine
- Intramuscular Injection
- Intravenous (IV)
- Investigational New Drug (IND)
- IPV – Intrapulmonary Percussive Ventilators
- IR – Interventional Radiology
- Lipids
- Lung Transplant
- Lupus
- Macrolide
- Malabsorption
- Microbiology
- Microorganism
- MRSA – Methicillin-resistant Staphylococcus Aureus
- Mucociliary Clearance
- Mucolytics
- Mucomyst
- Mucus
- Mucus Membrane
- Mutation
- National Institutes of Health (NIH)
- Neutrophil
- New Drug Application (NDA)
- Non-Invasive
- NSAIDs
- Off-Label Use
- Open-Label Trial
- Organism
- Orphan Drugs
- Pancreas
- Pancreatic Duct
- Phase 1 Trials
- Phase 2 Trials
- Phase 3 Trials
- Phase 4 Trials
- Phlegm
- PIC Line
- Placebo
- Placebo Effect
- Placebo-Controlled Study
- Pneumonia
- Portacath (Port)
- Pre-clinical
- Principal Investigator (PI)
- Procedure
- Pseudomonas Aeruginosa
- PT (Physical Therapist)
- Pulmonary Function Test (PFT)
- Pulmozyme
- Quality of Life
- Radiology
- Randomization
- Randomized Trial
- Research Coordinator
- Respiratory Inductance Plethysmography (RIP)
- Respiratory Therapist
- Risk–Benefit Analysis
- RN
- Run-in Period
- Secretion
- Side Effect
- Single-Blind Trials
- Spirometer
- Spirometry
- Sputum Culture
- Standard of Care
- Staph or Staphylococcus
- Subcutaneous injection
- Surfactant or Pulmonary Surfactant
- Sweat Test
- Systemic Disease
- Tissue
- Toxicity
- TPN
- Treatment IND
- Trendelenberg Position
- Universal Precautions
- Virus
- VRE – Vancomycin-resistant Enterococcus
- Xopenex